# Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

> **NCT07533305** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Henan University of Science and Technology** · enrollment: 50 (estimated)

## Conditions studied

- QL1706
- ESCC
- First-line Therapy

## Interventions

- **DRUG:** QL1706 plus nab-paclitaxel and cisplatin

## Key facts

- **NCT ID:** NCT07533305
- **Lead sponsor:** The First Affiliated Hospital of Henan University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07533305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07533305, "Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07533305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*